Astrazeneca Pharma India: New CFO Appointed, Approval for Child Breathing Difficulty Drug

3 Oct 2023 , 12:23 PM

Astrazeneca Pharma India’s stock price declines by 0.6% to Rs 4,476.10 on October 3 following recent CFO appointment and drug import approval. Bhavana Agrawal takes over as CFO from October 1, succeeding Rajesh Marwaha, who retired on September 30. Agrawal has a prior CFO experience at GE Healthcare.

The company gains CDSCO approval to import Palivizumab, a drug used to prevent severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk children, necessitating hospitalization.

For feedback and suggestions, write to us at [e-mail]